Overview A Study of BPI-452080 in Subjects With Solid Tumors Status: Not yet recruiting Trial end date: 2025-10-31 Target enrollment: Participant gender: Summary This open-label Phase 1 study will evaluate the efficacy and safety of BPI-452080 in patients with Solid Tumors Phase: Phase 1 Details Lead Sponsor: Betta Pharmaceuticals Co., Ltd.